【新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元】智通财经APP获悉,据港交所6月20

智通财经
Jun 22
【新股消息 | 眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元】智通财经APP获悉,据港交所6月20日披露,CLOUDBREAK PHARMA INC.(下称:拨康视云)通过港交所上市聆讯,建银国际、华泰国际为其联席保荐人。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10